QC: No

v1.6 06 December 2021

Short project title*:	PhEAST							
IRAS project ID* (or REC reference if no IRAS project ID is available):	304658							
Sponsor amendment reference number*:	MA_04_22							
Sponsor amendment date* (enter as DD/MM/YY):	18 May 2022							
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	This amendment co to participate in the	omprises of the addit PhEAST trial.	ion of a new site,a	and removal of site	es no longer abl			
				Specific stu	dy			
Project type (select):				Research tis	sue bank			
				Research da	tabase			
Has the study been reviewed by a UKECA-recognised Re-	search Ethics	Y	es	1	No			
Committee (REC) prior to this amendment?:				No NHS/HSC REC Ministry of Defence (MoDR No Scotland Nothern Irel				
What type of UKECA-recognised Research Ethics Commi is applicable? (select):	ttee (REC) review							
Is all or part of this amendment being resubmitted to the R Committee (REC) as a modified amendment (i.e. a substamendment previously given an unfavourable opinion)?		Y	es	ı	No			
Where is the NHS/HSC Research Ethics Committee (REC	that reviewed	England	Wales	Scotland Northern Ire				
the study based?:	,	Yes	No	No No				
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	product (CTIMP)	Y	es	ı	No			
Was the study a clinical investigation or other study of a m does the amendment make it one?:	edical device OR	Y	es	1	No			
Does this clinical investigation or other study of a med require a Notice of No Objection from MHRA Devices			Yes		No			
Did the study involve the administration of radioactive substrequiring ARSAC review, OR does the amendment introdu		Y	es	!	No			
Did the study involve the use of research exposures to ion (not involving the administration of radioactive substances amendment introduce this?:	•	Y	es	ı	No			
Did the study involve adults lacking capacity OR does the introduce this?:	amendment	Y	es	ı	No			
Did the study involve access to confidential patient information direct care team without consent OR does the amendment		Y	es	ı	No			
Did the study involve prisoners or young offenders who are supervised by the probation service OR does the amendments:		Y	es	I	No			
Did the study involve children OR does the amendment int	troduce this?:	Y	es	ı	No			
Did the study involve NHS/HSC organisations prior to this	amendment?:	Y	es	1	No			
Did the study involve non-NHS/HSC organisations OR documendment introduce them?:	es the	Y	es	ı	No			
		England	Wales	Scotland	Northern Irelar			
Lead nation for the study:		Yes	No	No	No			
Which nations had participating NHS/HSC organisations p	rior to this	Yes	Yes	Yes	Yes			
amendment? Which nations will have participating NHS/HSC organisation								

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1										
Area of change (select)*:	a of change (select)*: Participating Organisations									
Specific change (select - only available when area of change is selected first)*:	Addition of sites unde	Addition of sites undertaking the same activities as existing sites								
Further information (free text - note that this field will adapt to the amount of text entered):	Fairfield General Hos new site, with the PI t (WARRINGTON AND added as a new site,	eing Dr Narayana HALTON TEACH	moorthi Saravanai IING HOSPITALS	n; Warrington Áos	pital					
Applicability:	England Wales Scotland Northern Irela									
Where are the participating NHS/HSC organisations locate by this change?*:	ed that will be affected	Yes	No	No	No					
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categoriange):		ŀ	All							
			Remove all o	changes below						

Change 2										
Area of change (select)*:	ct)*: Participating Organisations									
Specific change (select - only available when area of change is selected first)*:	Early closure or withd	rawal of research	sites							
Further information (free text - note that this field will adapt to the amount of text entered):	The following sites an ASHFORD AND ST I HOSPITAL); KING'S TEACHING HOSPITA Glasgow and Clyde.	PETER'S HOSPITA COLLEGE HOSPI	ALS NHS FOUND TAL NHS FOUND	ATION TRUST (ST ATION TRUST; B	T PETERS LACKPOOL					
Applicability:		England	Wales	Scotland	Northern Ireland					
Where are the participating NHS/HSC organisations locate by this change?*:	ed that will be affected	Yes	No	Yes	No					
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categoriange):	A	All	So	Some						
				Remove all o	changes below					

Change 3										
Area of change (select)*:	Researchers									
Specific change (select - only available when area of change is selected first)*:	PI - New PI, or tempo	rary arrangements	s to cover the abse	ence of a PI						
Further information (free text - note that this field will adapt to the amount of text entered):	The following site will Georgina Randle will			Stockport NHS Fo	undation Trust)					
Applicability:		England	Wales	Scotland	Northern Ireland					
Where are the participating NHS/HSC organisations locate by this change?*:	ed that will be affected	Yes	No	No	No					
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categ change):		A	All	S	ome					
	Add another change									

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

,	
Name [first name and surname]*:	Angela Shone
Email address*:	sponsor@nottingham.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, <u>proceed to submit the amendment online</u>. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

								F	Review	bodie	s								
	UK wide:				Eng	land a	ınd Wa	ales:		Scot	land:		Northern Ireland:						
	0	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	g	HMPPS	A and HCRW Approval	C (AWIA)	ВРР	S (RAEC)	National coordinating function	CREC	C Data Guardians	Prisons	National coordinating function	
	REC	Sol	Col	AR	Rad	>	RE	CAG	ΣI	HRA	REC	PB	SPS	Nat	HSC	Σ Σ	Pris	Nai	Category:
Change 1:						(Y)				(Y)				(Y)					New site
Change 2:						(Y)				(Y)				(Y)					В
Change 3:						(Y)				(Y)				N					В
Overall reviews for the amendme	nt:																		
Full review:						N				N				N					
Notification only:						Υ				Υ				Υ					
Overall amendment type:	No	n-sub	stantia	l, no s	tudy-w	vide re	view r	equire	d										
Overall Category:	В																		